GT-201 Drug Asset Due Diligence Report 2026

This GT-201 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 11 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 1/2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether GT-201 can convert its TIL therapy, Gene therapy profile and IL-15 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	GT-201 (query alias: GT-201)
Modality / target	TIL therapy, Gene therapy; IL-15; IL-15 agonists, Immunologic cytotoxicity, T lymphocyte replacements
Highest global status	Phase 1/2
Originator	Zhuhai Grit Biotechnology Co., Ltd.
Active developers	Zhuhai Grit Biotechnology Co., Ltd.

The MCP disease footprint includes Advanced Malignant Solid Neoplasm, Squamous Cell Carcinoma of Head and Neck, Female Genital Neoplasms. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06834542	Early Phase 1	Terminated	1	Primary endpoint not disclosed in English source
NCT06519669	Not Applicable	Terminated	2	Primary endpoint not disclosed in English source
NCT06235242	Not Applicable	Terminated	2	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evaluation of autologous tumor-infiltrating lymphocytes (GT201) plus toripalimab in recurrent or metastatic head and neck cancer.

Phase 1; n=6; evaluation: Positive. Reported fields: TEAE(Grade ≥ 3) = Grade ≥ 3 AEs were primarily related to lymphodepletion and IL-2, and included cytopenia, neutropenia, lymphocytopenia, monocytopenia, hypokalemia, rash, and increased bilirubin; all resolved or improved to Grade ≤ 2 within 14 days

Armored TIL GT201 induces potent tumor-specific TCR expansion and durable antitumor responses in advanced solid tumor

Phase 1; n=12; evaluation: Positive. Reported fields: AE = most AEs were Grade 1-2, while Grade ≥3 events were attributable to lymphodepleting chemotherapy or IL-2 support and resolved within 14 days

Assessing the safety and efficacy of GT201: A first-in-class autologous tumor-infiltrating lymphocyte monotherapy in advanced solid tumors.

Phase 1/2; n=9; evaluation: Positive. Reported fields: DCR = 77.8 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

GT-201 addresses Advanced Malignant Solid Neoplasm, Squamous Cell Carcinoma of Head and Neck, Female Genital Neoplasms. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—TIL therapy, Gene therapy—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 22 matched transaction record(s) under the scope “target-level comparable: IL-15.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: IL-15 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-09-03	Xencor Inc Announces Termination Of Collaboration And License Agreement With Genentech Inc And F Hoffmann-La Roche Ltd	Phase 1	US$120.0M upfront; US$340.0M milestones; US$460.0M stated total
2026-05-27	HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen	Phase 2	Financial terms not disclosed
2026-01-11	Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo	Phase 2	US$75.0M upfront; US$425.0M milestones; US$500.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO